Virus-specific Cytotoxic T-lymphocytes Therapy (National Cancer Institute/MD Anderson Cancer Center)

病毒特异性细胞毒性T淋巴细胞疗法 (National Cancer Institute/MD Anderson Cancer Center)

Report date: 2024/01/02 20:03:52

Base Information

Drug NameVirus-specific Cytotoxic T-lymphocytes Therapy (National Cancer Institute/MD Anderson Cancer Center)
Drug Alias NameVirus-specific CTLsVirus-specific Cytotoxic T-lymphocytes
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionCytotoxic T lymphocytes replacements
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursBK Polyomavirus Infections +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Cancer InstituteThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursBK Polyomavirus Infections +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A